We are focused
on targeting Alzheimer's disease
As a clinical stage company, we develop advanced cannabinoid-based formulations for treating diseases and conditions including but not limited to Alzheimer’s disease, period cramps, premenstrual syndrome (PMS), and chronic pain. We have two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and
TGR-63, that have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease such as plaques and tangles.
IGC-AD1 is a tetrahydrocannabinol (THC) based formulation that is currently in a Phase 2B safety and efficacy clinical trial for agitation in dementia from Alzheimer’s (clinicaltrials.gov, NCT05543681).
Are you looking for a reliable
and experienced partner to support your Bussines?
We are a leading manufacturer and provider of nutraceutical products. We offer a wide range of services, including formulation, manufacturing, and packaging, to support businesses in the nutraceutical industry. With a portfolio of over 200 proprietary formulations and the ability to assist with any custom formulation or manufacturing needs. HH Processors specializes in producing a variety of nutraceutical products such as gummies, tinctures, personal protection solutions, topicals, capsules, and more. Service begins when the customer provides a concept, the team handles everything else to provide the manufactured product.
Are you a retailer, Wholesaler
or distributor
in the CBD industry?
Our two wellness brands, Holief and Sunday Seltzer.
We market two wellness brands, Holief and Sunday Seltzer. Holief targets women experiencing premenstrual syndrome and menstrual cramps and Sunday Seltzer targets lifestyle with a hemp (cannabinol CBD)-infused energy beverage brand.
Vertically Integrated with Strategic Operations Worldwide and a Historical Infrastructure Business
"Our Vision Is to Be a Major Player in Alzheimer's Treatment"
Ram Mukunda, CEO
Cannabis-based drugs have the potential to improve the lives of millions with Alzheimer’s Disease.
